High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
130.17M
+11.96%
-0.163
-4.31%
129.51M
+11.74%
-0.146
-14.14%
139.64M
+12.36%
-0.060
-24.5%
Estimates Revision
The market is revising Upward the revenue expectations for AtriCure, Inc. (ATRC) for FY2025, with the revenue forecasts being adjusted by 0.01% over the past three months. During the same period, the stock price has changed by -5.82%.
Revenue Estimates for FY2025
Revise Upward
+0.01%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-11.98%
In Past 3 Month
Stock Price
Go Down
-5.82%
In Past 3 Month
8 Analyst Rating
0Wall Street analysts forecast ATRC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATRC is 50.38 USD with a low forecast of 40.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
0 Hold
0 Sell
Strong Buy
0Current: 30.720
Low
40.00
Averages
50.38
High
60.00
0Current: 30.720
Low
40.00
Averages
50.38
High
60.00
Citizens Capital Markets
Daniel Stauder
Buy
Reiterates
$60
2025-04-02
Reason
Citizens Capital Markets
Daniel Stauder
Price Target
$60
2025-04-02
Reiterates
Buy
Reason
Canaccord Genuity
William Plovanic
Strong Buy
Maintains
$66 → $52
2025-03-28
Reason
Canaccord Genuity
William Plovanic
Price Target
$66 → $52
2025-03-28
Maintains
Strong Buy
Reason
Canaccord lowered the firm's price target on AtriCure to $52 from $66 and keeps a Buy rating on the shares. The firm updated its model folloing the company's Investor Day that both reiterated its 2025 guidance and provided an aspirational LRP that included three-year objectives as well as targets for 2030.
Needham
Mike Matson
Strong Buy
Reiterates
$51
2025-03-27
Reason
Needham
Mike Matson
Price Target
$51
2025-03-27
Reiterates
Strong Buy
Reason
JP Morgan
Lilia-Celine Lozada
Buy
Maintains
$51 → $46
2025-03-27
Reason
JP Morgan
Lilia-Celine Lozada
Price Target
$51 → $46
2025-03-27
Maintains
Buy
Reason
Needham
Mike Matson
Strong Buy
Reiterates
$51
2025-03-21
Reason
Needham
Mike Matson
Price Target
$51
2025-03-21
Reiterates
Strong Buy
Reason
Oppenheimer
Suraj Kalia
Buy
Maintains
$36 → $45
2025-02-13
Reason
Oppenheimer
Suraj Kalia
Price Target
$36 → $45
2025-02-13
Maintains
Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for AtriCure Inc (ATRC.O) is -62.37, compared to its 5-year average forward P/E of -49.77. For a more detailed relative valuation and DCF analysis to assess AtriCure Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-49.77
Current PE
-62.37
Overvalued PE
-37.32
Undervalued PE
-62.22
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
1170.79
Current EV/EBITDA
33.97
Overvalued EV/EBITDA
8464.57
Undervalued EV/EBITDA
-6122.98
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Undervalued
5Y Average PS
6.30
Current PS
2.95
Overvalued PS
9.50
Undervalued PS
3.10
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress areBuying! The buying amount has increased100%over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
ATRC News & Events
Events Timeline
(ET)
2025-04-29
16:05:26
AtriCure sees FY25 revenue $517M-$527M, consensus $522.85M
2025-04-29
16:04:40
AtriCure reports Q1 adjusted EPS (14c), consensus (22c)
2025-03-26 (ET)
2025-03-26
13:10:05
AtriCure sees 2028 revenue $750M+, adjusted EBITDA margin 14%
Sign Up For More Events
Sign Up For More Events
News
Preview
8.0
06-30NASDAQ.COMInteresting ATRC Put And Call Options For August 15th
Preview
4.0
04-30BenzingaVisa To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Wednesday
Preview
4.0
04-30BenzingaNeedham Maintains Buy on AtriCure, Lowers Price Target to $44
Sign Up For More News
People Also Watch
FAQ
What is AtriCure Inc (ATRC) stock price today?
What is AtriCure Inc (ATRC)'s business?
What is the price predicton of ATRC Stock?
What is AtriCure Inc (ATRC)'s revenue for the last quarter?
What is AtriCure Inc (ATRC)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for AtriCure Inc (ATRC)'s fundamentals?
How many employees does AtriCure Inc (ATRC). have?